Swissmedic, the Swiss agency for therapeutic products, has extended the use of remdesivir for COVID-19 patients treatment.
"Following a careful review in record time, Swissmedic – the Swiss Agency for Therapeutic Products – has decided to allow the temporary distribution of remdesivir. As a result, more COVID-19 patients can now immediately be treated while the authorisation documentation is still under review," they said in a statement.
"Products containing the active substance remdesivir and marketed under the brand name "Veklury" may be used in Swiss hospitals, without authorisation, for the treatment of COVID-19 patients until the official authorisation decision is issued or the corresponding emergency status is revoked."
According to the statement, "the product will also be made available to patients outside approved clinical trials and the approved compassionate use programme while the submitted authorisation application is being reviewed. Adverse reactions to the drug will be closely monitored in order to ensure patient safety."